臨床泌尿器科60巻7号

2006年06月発行

綜説

前立腺における神経内分泌細胞

著者： 舛森直哉¹

所属機関： ¹札幌医科大学泌尿器科

ページ範囲：P.439 - P.451

文献概要

　前立腺の上皮細胞は，分泌管腔細胞，基底細胞および神経内分泌（neuroendocrine：NE）細胞の3種類より構成されている。NE細胞より分泌されるNE因子は，自身や周囲の細胞に影響を及ぼすことにより正常前立腺における恒常性の維持に関与している。また，NE細胞は前立腺肥大症や前立腺癌の発生・進展，さらには，前立腺癌における内分泌抵抗性にも関与している可能性がある。前立腺癌に混在するNE細胞は，幹細胞の悪性化や腺癌細胞のNE様変化に由来すると推測される。NE細胞と前立腺癌の予後との関係は現時点では明確ではないが，NE細胞あるいはNE因子を標的とした治療が内分泌抵抗性前立腺癌や前立腺小細胞癌に対して有効である可能性がある。

参考文献

1）Bonkhoff H and Remberger K：Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth：a stem cell model. Prostate 28：98-106, 1996

2）Xue Y, Smedts F, Verhofstad A, et al：Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship：new perspectives. Prostate（Suppl）8：62-73, 1998

3）Uzgare AR, Xu Y and Isaacs JT：In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 91：196-205, 2004

4）Rumpold H, Heinrich E, Untergasser G, et al：Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro. Prostate 53：101-108, 2002

5）Aumuller G, Leonhardt M, Janssen M, et al：Neurogenic origin of human prostate endocrine cells. Urology 53：1041-1048, 1999

6）Untergasser G, Plas E, Pfister G, et al：Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells. Prostate 64：419-429, 2005

7）Acosta S, Dizeyi N, Pierzynowski S, et al：Neuroendocrine cells and nerves in the prostate of the guinea pig：effects of peripheral denervation and castration. Prostate 46：191-199, 2001

8）di Sant'Agnese PA：Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 23：287-296, 1992

9）Weaver MG, Abdul-Karim FW and Srigley JR：Paneth cell-like change and small cell carcinoma of the prostate. Two divergent forms of prostatic neuroendocrine differentiation. Am J Surg Pathol 16：1013-1016, 1992

10）Abrahamsson PA, Wadstrom LB, Alumets J, et al：Peptide-hormone-and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 182：298-307, 1987

11）Sheaff MT, Martin JE, Badenoch DF, et al：beta hCG as a prognostic marker in adenocarcinoma of the prostate. J Clin Pathol 49：329-332, 1996

12）Abrahamsson PA, Dizeyi N, Alm P, et al：Calcitonin and calcitonin gene-related peptide in the human prostate gland. Prostate 44：181-186, 2000

13）Ritchie CK, Thomas KG, Andrews LR, et al：Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 30：183-187, 1997

14）Chigurupati S, Kulkarni T, Thomas S, et al：Calcitonin stimulates multiple stages of angiogenesis by directly acting on endothelial cells. Cancer Res 65：8519-8529, 2005

15）Abrahamsson PA, Falkmer S, Falt K, et al：The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an“endocrine marker”. Pathol Res Pract 185：373-380, 1989

16）Huttner WB, Gerdes HH and Rosa P：The granin（chromogranin/secretogranin）family. Trends Biochem Sci 16：27-30, 1991

17）Schmid KW, Helpap B, Totsch M, et al：Immunohistochemical localization of chromogranins A and B and secretograninⅡ in normal, hyperplastic and neoplastic prostate. Histopathology 24：233-239, 1994

18）Cecio A, Cocca T, Masotti MT, et al：CCK-containing paraneurons in human adenomatous prostate. Biosci Rep 13：251-258, 1993

19）Aprikian AG, Han K, Guy L, et al：Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate（Suppl）8：52-61, 1998

20）Levine L, Lucci JA 3rd, Pazdrak B, et al：Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 63：3495-3502, 2003

21）Lacoste J, Aprikian AG and Chevalier S：Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility. Mol Cell Endocrinol 235：51-61, 2005

22）Polge A, Gaspard C, Mottet N, et al：Neurohormonal stimulation of histamine release from neuroendocrine cells of the human adenomatous prostate. Prostate 34：1-9, 1998

23）Kondo S, Tashima Y and Morita T：Effect of cimetidine on the density of adrenergic alpha-1 and alpha-2 receptors in the rat whole prostate. Tohoku J Exp Med 167：163-166, 1992

24）di Sant'Agnese PA, de Mesy Jensen KL, Churukian CJ, et al：Human prostatic endocrine-paracrine（APUD）cells. Distributional analysis with a comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains. Arch Pathol Lab Med 109：607-612, 1985

25）Martin R, Fraile B, Peinado F, et al：Immunohistochemical localization of protein gene product 9.5, ubiquitin, and neuropeptide Y immunoreactivities in epithelial and neuroendocrine cells from normal and hyperplastic human prostate. J Histochem Cytochem 48：1121-1130, 2000

26）Magni P and Motta M：Expression of neuropeptide Y receptors in human prostate cancer cells. Ann Oncol 12（Suppl 2）：S27-29, 2001

27）Iwamura M, Wu G, Abrahamsson PA, et al：Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 43：667-674, 1994

28）Iwamura M, Abrahamsson PA, Foss KA, et al：Parathyroid hormone-related protein：a potential autocrine growth regulator in human prostate cancer cell lines. Urology 43：675-679, 1994

29）Jimenez N, Calvo A, Martinez A, et al：Expression of adrenomedullin and proadrenomedullin N-terminal 20 peptide in human and rat prostate. J Histochem Cytochem 47：1167-1178, 1999

30）Calvo A, Abasolo I, Jimenez N, et al：Adrenomedullin and proadrenomedullin N-terminal 20 peptide in the normal prostate and in prostate carcinoma. Microsc Res Tech 57：98-104, 2002

31）Abdul M, Anezinis PE, Logothetis CJ, et al：Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 14：1215-1220, 1994

32）di Sant'Agnese PA and de Mesy Jensen KL：Somatostatin and/or somatostatin-like immunoreactive endocrine-paracrine cells in the human prostate gland. Arch Pathol Lab Med 108：693-696, 1984

33）Brevini TA, Bianchi R and Motta M：Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP：possible mechanism of action. J Clin Endocrinol Metab 77：626-631, 1993

34）Harper ME, Glynne-Jones E, Goddard L, et al：Vascular endothelial growth factor（VEGF）expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 74：910-916, 1996

35）Borre M, Nerstrom B and Overgaard J：Association between immunohistochemical expression of vascular endothelial growth factor（VEGF）, VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 6：1882-1890, 2000

36）Nakada SY, di Sant'Agnese PA, Moynes RA, et al：The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 53：1967-1970, 1993

37）Xue Y, Verhofstad A, Lange W, et al：Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2：cell kinetic features of neuroendocrine cells in the human prostate. Am J Pathol 151：1759-1765, 1997

38）Bonkhoff H：Neuroendocrine cells in benign and malignant prostate tissue：morphogenesis, proliferation, and androgen receptor status. Prostate（Suppl）8：18-22, 1998

39）Lee KL and Peehl DM：Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 172：1784-1791, 2004

40）Untergasser G, Madersbacher S and Berger P：Benign prostatic hyperplasia：age-related tissue-remodeling. Exp Gerontol 40：121-128, 2005

41）Cockett AT, di Sant'Agnese PA, Gopinath P, et al：Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. Urology 42：512-519, 1993

42）Berry SJ, Coffey DS, Walsh PC, et al：The development of human benign prostatic hyperplasia with age. J Urol 132：474-479, 1984

43）Abrahamsson PA：Neuroendocrine differentiation in prostatic carcinoma. Prostate 39：135-148, 1999

44）Bonkhoff H, Stein U and Remberger K：Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 423：291-294, 1993

45）Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, et al：Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 100：393-398, 1993

46）Guate JL, Escaf S, Menendez CL, et al：Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma：effect of hormonal treat-ment. Urol Int 59：149-153, 1997

47）Bonkhoff H, Stein U and Remberger K：Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate：simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 25：42-46, 1994

48）Masumori N, Thomas TZ, Chaurand P, et al：A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 61：2239-2249, 2001

49）Jiborn T, Bjartell A and Abrahamsson PA：Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment.

50）Ahlgren G, Pedersen K, Lundberg S, et al：Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 42：274-279, 2000

51）Casella R, Bubendorf L, Sauter G, et al：Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol 160：406-410, 1998

52）Burchardt T, Burchardt M, Chen MW, et al：Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 162：1800-1805, 1999

53）Wright ME, Tsai MJ and Aebersold R：Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 17：1726-1737, 2003

54）Noordzij MA, van Weerden WM, de Ridder CM, et al：Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol 149：859-871, 1996

55）Jongsma J, Oomen MH, Noordzij MA, et al：Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol 154：543-551, 1999

56）Qiu Y, Robinson D, Pretlow TG, et al：Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A 95：3644-3649, 1998

57）Mori S, Murakami-Mori K and Bonavida B：Interleukin-6 induces G1 arrest through induction of p27（Kip1）, a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 257：609-614, 1999

58）Wang Q, Horiatis D and Pinski J：Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer 111：508-513, 2004

59）Diaz M, Abdul M and Hoosein N：Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and-2. Prostate Suppl 8：32-36, 1998

60）Hsieh TC, Xu W and Chiao JW：Growth regulation and cellular changes during differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte-conditioned medium. Exp Cell Res 218：137-143, 1995

61）Bang YJ, Pirnia F, Fang WG, et al：Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A 91：5330-5334, 1994

62）Cox ME, Deeble PD, Lakhani S, et al：Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible：implications for prostate cancer progression. Cancer Res 59：3821-3830, 1999

63）Sauer CG, Roemer A and Grobholz R：Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma. Prostate 66：227-234, 2006

64）Tainio H：Peptidergic innervation of the human prostate, seminal vesicle and vas deferens. Acta Histochem 97：113-119, 1995

65）Gutierrez-Canas I, Juarranz MG, Collado B, et al：Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. Prostate 63：44-55, 2005

66）Tetu B, Ro JY, Ayala AG, et al：Small cell carcinoma of the prostate. PartⅠ. A clinicopathologic study of 20 cases. Cancer 59：1803-1809, 1987

67）Oesterling JE, Hauzeur CG and Farrow GM：Small cell anaplastic carcinoma of the prostate：a clinical, pathological and immunohistological study of 27 patients. J Urol 147：804-807, 1992

68）Helpap B and Kollermann J：Undifferentiated carcinoma of the prostate with small cell features：immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 434：385-391, 1999

69）Asmis TR, Reaume MN, Dahrouge S, et al：Genitourinary small cell carcinoma：a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center. BJU Int 97：711-715, 2006

70）Helpap B and Kollermann J：Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence? Virchows Arch 438：86-91, 2001

71）Bonkhoff H, Wernert N, Dhom G, et al：Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 19：91-98, 1991

72）Segawa N, Mori I, Utsunomiya H, et al：Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 51：452-459, 2001

73）Segal NH, Cohen RJ, Haffejee Z, et al：bcl-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 118：616-618, 1994

74）di Sant'Agnese PA：Neuroendocrine differentiation in prostatic carcinoma：an update. Prostate（Suppl）8：74-79, 1998

75）Masumori N, Tsuchiya K, Tu WH, et al：An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol 171：439-442, 2004

76）Uchida K, Masumori N, Takahashi A, et al：Characterization of prostatic neuroendocrine cell line established from neuroendocrine carcinoma of transgenic mouse allograft model. Prostate 62：40-48, 2005

77）Uchida K, Masumori N, Takahashi A, et al：Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate 66：536-545, 2006

78）Angelsen A, Syversen U, Haugen OA, et al：Neuroendocrine differentiation in carcinomas of the prostate：do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 30：1-6, 1997

79）Ather MH and Abbas F：Prognostic significance of neuroendocrine differentiation in prostate cancer. Eur Urol 38：535-542, 2000

80）Cohen MK, Arber DA, Coffield KS, et al：Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression.

81）Noordzij MA, van der Kwast TH, van Steenbrugge GJ, et al：The prognostic influence of neuroendocrine cells in prostate cancer：results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 62：252-258, 1995

82）Weinstein MH, Partin AW, Veltri RW, et al：Neuroendocrine differentiation in prostate cancer：enhanced prediction of progression after radical prostatectomy. Hum Pathol 27：683-687, 1996

83）Bubendorf L, Sauter G, Moch H, et al：Ki-67 labelling index：an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178：437-441, 1996

84）Abrahamsson PA, Cockett AT and di Sant'Agnese PA：Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate（Suppl）8：37-42, 1998

85）Ahlgren G, Pedersen K, Lundberg S, et al：Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. Urology 56：1011-1015, 2000

86）Cohen RJ, Glezerson G, Haffejee Z, et al：Prostatic carcinoma：histological and immunohistological factors affecting prognosis. Br J Urol 66：405-410, 1990

87）Krijnen JL, Bogdanowicz JF, Seldenrijk CA, et al：The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy［see comments］. J Urol 158：171-174, 1997

88）Lilleby W, Paus E, Skovlund E, et al：Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate 46：126-133, 2001

89）Isshiki S, Akakura K, Komiya A, et al：Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 167：512-515, 2002

90）Kamiya N, Akakura K, Suzuki H, et al：Pretreatment serum level of neuron specific enolase（NSE）as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol 44：309-314；discussion 314, 2003

91）Yashi M, Nukui A, Kurokawa S, et al：Elevated serum progastrin-releasing peptide（31-98）level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate 56：305-312, 2003

92）Grossmann ME, Huang H and Tindall DJ：Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93：1687-1697, 2001

93）Debes JD and Tindall DJ：Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351：1488-1490, 2004

94）Jin RJ, Wang Y, Masumori N, et al：NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 64：5489-5495, 2004

95）Nishimura K, Ting HJ, Harada Y, et al：Modulation of androgen receptor transactivation by gelsolin：a newly identified androgen receptor coregulator. Cancer Res 63：4888-4894, 2003

96）Chuang CK, Wu TL, Tsao KC, et al：Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer. J Formos Med Assoc 102：480-485, 2003

97）Cabrespine A, Guy L, Gachon F, et al：Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. J Urol 175：1347-1352, 2006

98）Sasaki T, Komiya A, Suzuki H, et al：Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol 48：224-229；discussion 229-230, 2005

99）Cussenot O, Villette JM, Cochand-Priollet B, et al：Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate（Suppl）8：43-51, 1998

100）Berruti A, Dogliotti L, Mosca A, et al：Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 12（Suppl 2）：S153-157, 2001

101）Taplin ME, George DJ, Halabi S, et al：Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 66：386-391, 2005

102）Berruti A, Mosca A, Tucci M, et al：Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 12：109-117, 2005

103）Hvamstad T, Jordal A, Hekmat N, et al：Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 44：215-221, 2003

104）Hansson J, Bjartell A, Gadaleanu V, et al：Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate 53：50-59, 2002

105）Sciarra A, Bosman C, Monti G, et al：Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma. J Urol 172：1775-1783, 2004

106）Dizeyi N, Bjartell A, Nilsson E, et al：Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 59：328-336, 2004

107）Reile H, Armatis PE and Schally AV：Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145：internalization of receptor bound 125I-（Tyr4）bombesin by tumor cells. Prostate 25：29-38, 1994

108）Noda K, Nishiwaki Y, Kawahara M, et al：Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346：85-91, 2002